Updated just now · Live
Stock analysis, price data, and AI-powered insights for Immatics NV (IMTX).
Immatics NV operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for IMTX.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). IMTX Stock Intelligence Report. [stoxpulse.com/stocks/imtx]
Disclaimer: The information on this page about Immatics NV (IMTX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Immatics NV.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Immatics Announces Four Upcoming Oral Presentation...
4h ago
Immatics Announces Its Abstract Regarding Pediatri...
3d ago
StoxPulse AI results for IMTX: Pulse Score 51.5/100. Primary sentiment trends from 4 news sources and 0 SEC filings indicate a bullish outlook.
Market Cap
$1.51B
P/E Ratio
—
EPS
—
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
Immatics Announces Its Abstract Regarding Pediatric Participant Treatment With PRAME-Directed Cell Therapy Using Its PRAME T-Cell Receptor Accpected For Poster Presentation At American Association For Cancer Research Annual Meeting 2026
Immatics N : PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma